陳尚鴻 主治醫師-論文

PUBLICATIONS

(*=corresponding author)

  1. Chen PC, Yeh YM, Lin BW, Chan RH, Su PF, Liu YC, Lee CT, Chen SH*, Lin PC. A Prediction Model for Tumor Recurrence in Stage II–III Colorectal Cancer Patients: From a Machine Learning Model to Genomic Profiling. Biomedicines. 2022 Feb 1;10(2):340. https://doi.org/10.3390/biomedicines10020340. (IF: 6.1; Rank: 65/295 in Biochemistry & Molecular Biology)
  2. Huang YH, Lin PC, Su WC, Chan RH, Chen PC, Lin BW, Shen MR, Chen SH*, Yeh YM. Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer. Diagnostics (Basel). 2021 Dec 8;11(12):2308. doi: 10.3390/diagnostics11122308. (IF: 3.7; Rank: 51/315 in Medicine, General & Internal)
  3. Hsueh WT, Chen SH, Chien CH, Chou SW, Chi PI, Chu JM, Chang KY. SOD2 enhancement by long-term inhibition of the PI3K pathway confers multi-drug resistance and enhanced tumor-initiating features in head and neck cancer. Int. J. Mol. Sci. 2021, 22(20), 11260; https://doi.org/10.3390/ijms222011260. (IF: 5.9; Rank: 67/297 in Biochemistry & Molecular Biology)
  4. Chang KY, Chiang NJ, Wu SY, Yen CJ, Chen SH, Yeh YM, Li CF, Feng X, Wu K, Johnston A, Bomalaski JS, Wu BW, Gao J, Subudhi SK, Kaseb AO, Blando JM, Yadav SS, Szlosarek PW, Chen LT. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. Oncoimmunology. 2021 Jul 12;10(1):1943253. (IF: 8.1; Rank: 37/242 in Oncology)
  5. Wu HC, Lin WL, Lin CL, Lin CY, Chen SW, Chen YX, Chen CH, Lee SW, Chen SH, Tsao CJ, Huang WT, Guo HR. Age as a modifier of the effects of chemoradiotherapy with infusional 5-fluorouracil after D2 dissection in gastric cancer. Aging (Albany NY). 2021 Jul 5;13(13):17337-17348. (IF: 5.7; Rank: 16/66 in Geriatrics & Gerontology)
  6. Chan RH, Lin PC, Chen SH, Lin SC, Chen PC, Lin BW, Shen MR, Yeh YM. Clinical utility of a cell-free DNA assay in patients with colorectal cancer. Front Oncol. 2021 Mar 19;11:589673. (IF: 4.8; Rank: 69/244 in Oncology)
  7. Chen SH, Hsiao SY, Chang KY, Chang JY. New insights into oral squamous cell carcinoma: from clinical aspects to molecular tumorigenesis. Int J Mol Sci. 2021 Feb 24;22(5):2252. (IF: 4.6; Rank: 74/297 in Biochemistry & Molecular Biology)
  8. Chen SH, Huang WT, Kao WC, Hsiao SY, Pan HY, Fang CW, Shiue YL, Chou CL, Li CF. O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma. J Biomed Sci. 2021 Jan 4;28(1):2. (IF: 5.8; Rank: 17/139 in Medicine, Research & Experimental)
  9. Yeh YM, Lin PC, Lee CT, Chen SH, Lin BW, Lin SC, Chen PC, Chan RH, Shen MR. Treatment monitoring of colorectal cancer by integrated analysis of plasma concentration and sequencing of circulating tumor DNA. Mol Cancer. 2020 Oct 26;19(1):150. (IF: 15.3; Rank: 10/244 in Oncology)
  10. Sheu MJ, Chou CL, Yang CC, Lee SW, Tian YF, Lin CY, Hsiao SY, Chen SH, Huang WT. Low BRCA2 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy. Pathol Res Pract. 2020 May;216(5):152922. (IF: 2.1; Rank: 43/78 in Pathology)
  11. Chien CH, Chuang JY, Yang ST, Yang WB, Chen PY, Hsu TI, Huang CY, Lo WL, Yang KY, Liu MS, Chu JM, Chung PH, Liu JJ, Chou SW, Chen SH, Chang KY. Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets. J Biomed Sci. 2019 Oct 19;26(1):77. (IF: 5.2; Rank: 20/136 in Medicine, Research & Experimental)
  12. Lin TY, Chan HH, Chen SH, Sarvagalla S, Chen PS, Coumar MS, Cheng SM, Chang YC, Lin CH, Leung E, Cheung CHA. BIRC5/Survivin is a novel ATG12-ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells. Autophagy. 2019 Oct 15:1-18. (IF: 11.1; Rank: 14/193 in Cell Biology)
  13. Chen SH, Chang JY. New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int J Mol Sci. 2019 Aug 24;20(17). pii: E4136. (IF: 4.2; Rank: 78/299 in Biochemistry & Molecular Biology)
  14. Chen SH, Tsai HL, Jiang JK, Sung YC, Huang CW, Yeh YM, Chen LT, Wang JY. Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol. BMC Cancer. 2019 Jun 28;19(1):640. (IF: 2.9; Rank: 121/230 in Oncology)
  15. Chiu CC, Lin WL, Shi HY, Huang CC, Chen JJ, Su SB, Lai CC, Chao CM, Tsao CJ, Chen SH, Wang JJ. Comparison of oncologic outcomes in laparoscopic versus open surgery for non-metastatic colorectal cancer: personal experience in a single institution. J Clin Med. 2019 Jun 19;8(6). (IF: 5.7; Rank: 15/160 in Medicine, General & Internal)
  16. Yeh YM, Lee CH, Chen SH, Lee CT, Chen YL, Lin BW, Lin SC, Chan RH, Lee JC, Shen MR, Lin PC. Comprehensive assessment of HER2 alteration in a colorectal cancer cohort: from next-generation sequencing to clinical significance. Cancer Manag Res. 2019:11: 7867– (IF: 2.2; Rank: 168/230 in Oncology)
  17. Hsu SH, Chen SH, Kuo CC, Chang JY. Ubiquitin-conjugating enzyme E2 B regulates the ubiquitination of O6-methylguanine-DNA methyltransferase and BCNU sensitivity in human nasopharyngeal carcinoma cells. Biochem Pharmacol. 2018 Dec;158:327-38. (IF: 4.2; Rank: 36/261 in Pharmacology & Pharmacy)
  18. Chen TJ, He HL, Shiue YL, Yang CC, Lin LC, Tian YF, Chen SH*. High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy. Int J Med Sci. 2018 Jul 30;15(11):1171-8. (IF: 2.3; Rank: 46/155 in Medicine, General & Internal)
  19. Huang WT, Tsai YH, Chen SH, Kuo CW, Kuo YL, Lee KT, Chen WC, Wu PC, Chuang CY, Cheng SM, Lin CH, Leung EY, Cheung CH. HDAC2 and HDAC5 up-regulations modulate survivin and miR-125a-5p expressions and promote hormone therapy resistance in estrogen receptor positive breast cancer cells. Front Pharmacol. 2017 Dec 13;8:902. (IF: 4.4; Rank: 33/257 in Pharmacology & Pharmacy)
  20. Lee JY, Kuo CW, Tsai SL, Cheng SM, Chen SH, Chan HH, Lin CH, Lin KY, Li CF, Kanwar JR, Leung EY, Cheung CC, Huang WJ, Wang YC, Cheung CH. Inhibition of HDAC3- and HDAC6-promoted survivin expression plays an important role in SAHA-induced autophagy and viability reduction in breast cancer cells. Front Pharmacol. 2016 Mar 31;7:81. (IF: 4.4; Rank: 33/255 in Pharmacology & Pharmacy)
  21. Chen SH, Kuo CC, Li CF, Cheung CH, Tsou TC, Chiang HC, Yang YN, Chang SL, Lin LC, Pan HY, Chang KY, Chang JY. O6 -methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma. Int J Cancer. 2015 Sep 15;137(6):1291-305. (IF: 5.1; Rank: 31/211 in Oncology)
  22. Hsu JY, Chang KY, Chen SH, Lee CT, Chang ST, Cheng HC, Chang WC, Chen BK. Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation. Oncotarget. 2015 Jan 30;6(3):1723-39. (IF: 6.4; Rank: 21/211 in Oncology)
  23. Cheng SM, Chang YC, Liu CY, Lee JYC, Chan HH, Kuo CW, Lin KY, Tsai SL, Chen SH, Li CF, Leung E, Kanwar JR, Huang CC, Chang JY, Cheung CHA. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagydependent DNA damage in breast cancer cells. Br J Pharmacol. 2015 Jan;172(1):214-34. (IF: 4.8; Rank: 24/255 in Pharmacology & Pharmacy)
  24. Li CF, He HL, Wang JY, Huang HY, Wu TF, Hsing CH, Lee SW, Lee HH, Fang JL, Huang WT, Chen SH*. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy. J Clin Pathol. 2014 Dec;67(12):1056-61. (IF: 2.6; Rank: 25/76 in Pathology)
  25. Lin CY, Sheu MJ, Li CF, Lee SW, Lin LC, Wang YF, Chen SH*. Deficiency in asparagine synthetase expression in rectal cancers receiving concurrent chemoradiotherapy: negative prognostic impact and therapeutic relevance. Tumour Biol. 2014 Jul;35(7):6823-30. (IF: 2.8; Rank: 93/203 in Oncology)
  26. Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, Huang YC, Chen SH, Chang JY. Survivin – biology and potential as a therapeutic target in oncology. Onco Targets Ther. 2013 Oct 16;6:1453-62. (IF: 2.1; Rank: 80/160 in Biotechnology & Applied Microbiology)
  27. Chang KY, Tsai SY, Chen SH, Tsou HH, Yen CJ, Liu KJ, Fang HL, Wu HC, Chuang BF, Chou SW, Tang CK, Liu SY, Lu PJ, Yen CY, Chang JY. Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. J Biomed Sci. 2013 Jun 27;20:43. (IF: 2.5; Rank: 57/121 in Medicine, Research & Experimental)
  28. Tian YF, Chen TJ, Lin CY, Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Shiue YL, Huang HY, Pan HY, Li CF, Chen SH*. SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemo-radiotherapy and represents a therapeutic target with high potential. Tumour Biol. 2013 Apr;34(2):1107-17. (IF: 2.5; Rank: 102/197 in Oncology)
  29. Lin CY, Tian YF, Wu LC, Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Wang YH, Shiue YL, Wu WR, Huang HY, Hsu HP, Li CF, Chen SH*. Rsf-1 expression in rectal cancer: with special emphasize on the independent prognostic value after neoadjuvant chemoradiation. J Clin Pathol. 2012 Aug; 65(8):687-92. (IF: 2.3; Rank: 32/79 in Pathology)
CONFERENCE PAPERS
  1. Real-world utilization of the 21-gene assay in Taiwanese patients with early female breast cancer. 2021 Annual Meeting of Taiwan Society of Internal Medicine. December, 2021.
  2. Real-world treatment outcome of cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive metastatic breast cancer. 2020 Annual Meeting of Taiwan Society of Internal Medicine. November, 2020 (Outstanding Poster Award).
  3. MGMT promoter methylation regions correlating to gene expression in glioblastomas after temozolomide treatment. The 78th Annual Meeting of the Japanese Cancer Association. September, 2019.
  4. The clinical implication of O6-methylguanine DNA methyltransferase in rectal cancers. The 77th Annual Meeting of the Japanese Cancer Association. September, 2018.
  5. A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers. American Society of Clinical Oncology Annual Meeting; May, 2018.
  6. O6BG modulates the activity of homologous recombination and its clinical application. The 76th Annual Meeting of the Japanese Cancer Association. September, 2017.
  7. Improved survivals of chemoradiotherapy with infusional 5-fluorouracil after D2 resection in younger gastric cancer. The 21th Taiwan Joint Caner Conference Annual Meeting; May, 2016.
  8. Deficiency in asparagine synthetase expression predicts negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy. The 19th Taiwan Joint Caner Conference Annual Meeting; May, 2014.
  9. ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). American Society of Clinical Oncology Annual Meeting; May, 2012.
  10. Expression of O6-Methylguanine DNA Methyltransferase predicts response and survival for rectal cancer patients receiving neoadjuvant chemoradiotherapy. International symposium on clinical and cancer research; May, 2012.
  11. Rsf-1 expression in rectal cancer: with special emphasize on the independent prognostic value after neoadjuvant chemoradiation. International symposium on clinical and cancer research; May, 2012.
  12. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates therapeutic efficacy of platinum drugs and its clinical significance. The European multidisciplinary cancer congress; September, 2011.
  13. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates therapeutic efficacy of platinum drugs and its clinical significance. The 16th Taiwan Joint Caner Conference Annual Meeting; May, 2011.
BOOK CHAPTER
  1. Chen SH, Cheung CHA. Challenges in treating Estrogen-Positive Breast Cancer. In: Wahid Ali Khan, Editor. Estrogen, Chapter 1: London, UK: IntechOpen Press, 2018.
Share Button

Comments are closed.